Advanced NSCLC Monotherapy Treatment

Patient
Profiles

Hypothetical patients based on those studied in EMPOWER-Lung 1

Considering LIBTAYO monotherapy in advanced NSCLC

What patients may be appropriate for monotherapy treatment? Look through the hypothetical profiles
below to find out more. All patients were unremarkable for EGFR, ALK, or ROS1 aberrations.



  • ALK=anaplastic lymphoma kinase; EGFR=epidermal growth factor receptor; NSCLC=non–small cell lung cancer; PD-L1=programmed death ligand 1; ROS1=ROS proto-oncogene 1, receptor tyrosine kinase.